Thrombotic Complications in Multiple Myeloma: A Case Report and the Literature Review_West China Medical Journal

Authors：

WANG Xin ^1,2 , HUANG Jie ¹ , DENG Chengqi ¹ , YANG Yiming ¹ ,  NIU Ting ¹

1. Department of Hematology & Hematology Research Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China; 2. Department of Hematology, Suining Central Hospital, Suining, Sichuan 629000, P. R. China;

Corresponding author：

NIU Ting, Email: wangxin_2003_2003@126.com

Keywords：

多发性骨髓瘤; 合并症; 血栓形成; 诊断; 治疗

DOI：

CNKI: 51-1356/R.20120215.1036.001

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　提高对多发性骨髓瘤合并动静脉血栓形成的临床诊治水平。方法　报道1例表现为反复胸腔积液，同时合并反复、多处静脉和动脉血栓形成患者的临床资料，并复习文献。结果　该例62岁老年女性患者，合并右侧下肢静脉、肾动脉、脑动脉、颈动脉、肺动脉血栓反复形成，检查后明确诊断为多发性骨髓瘤IgG λ型、原发性淀粉样变，合并多处动静脉血栓形成，给予美法仑+泼尼松（MP）方案化疗和抗血小板、抗凝治疗后症状改善，随访13个月病情稳定，无新发血栓形成。结论　多发性骨髓瘤可能合并动静脉血栓形成等不典型表现，需要进一步提高认识。

Citation： WANG Xin,HUANG Jie,DENG Chengqi,YANG Yiming,NIU Ting. Thrombotic Complications in Multiple Myeloma: A Case Report and the Literature Review. West China Medical Journal, 2012, 27(2): 179-181. doi: CNKI: 51-1356/R.20120215.1036.001 Copy

1.	SwSwerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. 4th ed. Lyon: International agency for research on ca ncer (IARC) Press, 2008: 202.
2.	Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study[J]. Blood, 2010, 115(24): 4991-4998.
3.	魏晓娜, 檀金川. 以下肢动脉血栓为首发症状的多发性骨髓瘤1例[J]. 临床荟萃, 2010, 25(7): 619-620.
4.	刘增艳. 多发性骨髓瘤血栓形成及防治的研究进展[J]. 国际输血及血液学杂志, 2007, 30(6): 499-501.
5.	Auwerda JJ , Sonnevel d P , de-Maat MP, et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma[J]. Haematologica, 2007, 92(2): 279-280.
6.	Ehce F, Fink L, Tricot G, et al. Acquired resistance to activated proteinC (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism[J]. Br J Haematol, 2006, 134(4): 399-405.
7.	Ying KJ, Zhou Y, Jiang H, et al. Multiple myeloma with pulmonary embolism: a case report[J]. Chin Med J (Engl), 2006, 119(17): 1481-1484.
8.	Uaprasert N, Voorhees PM, Mackman N, et al. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis[J]. Eur J Cancer, 2010, 46(10): 1790-1799.
9.	Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma[J]. N Engl J Med, 2006, 354(10): 1021-1030.
10.	Palumbo A, Cavo M, Bringhen S, et al. A prospective, randomized, phaseⅢ study of enoxaparin versus aspirin versus low-fixed-dose of warfarin in newly diagnosed myeloma patients treated with thalidomide containing regimens[J]. ASH Annual Meeting Abstracts, 2007, 110(11): 310.
11.	Richardson PG, Mitsiades C, Schlossman R, et al. Bortezomib in the front-line treatment of multiple myeloma[J]. Expert Rev Anticancer Ther, 2008, 8(7): 1054-1072.
12.	Kristinsson SY. Thrombosis in multiple myeloma[J]. Hematology, 2010, 2010(1): 437-444.

1. SwSwerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. 4th ed. Lyon: International agency for research on ca ncer (IARC) Press, 2008: 202.
2. Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study[J]. Blood, 2010, 115(24): 4991-4998.
3. 魏晓娜, 檀金川. 以下肢动脉血栓为首发症状的多发性骨髓瘤1例[J]. 临床荟萃, 2010, 25(7): 619-620.
4. 刘增艳. 多发性骨髓瘤血栓形成及防治的研究进展[J]. 国际输血及血液学杂志, 2007, 30(6): 499-501.
5. Auwerda JJ , Sonnevel d P , de-Maat MP, et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma[J]. Haematologica, 2007, 92(2): 279-280.
6. Ehce F, Fink L, Tricot G, et al. Acquired resistance to activated proteinC (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism[J]. Br J Haematol, 2006, 134(4): 399-405.
7. Ying KJ, Zhou Y, Jiang H, et al. Multiple myeloma with pulmonary embolism: a case report[J]. Chin Med J (Engl), 2006, 119(17): 1481-1484.
8. Uaprasert N, Voorhees PM, Mackman N, et al. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis[J]. Eur J Cancer, 2010, 46(10): 1790-1799.
9. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma[J]. N Engl J Med, 2006, 354(10): 1021-1030.
10. Palumbo A, Cavo M, Bringhen S, et al. A prospective, randomized, phaseⅢ study of enoxaparin versus aspirin versus low-fixed-dose of warfarin in newly diagnosed myeloma patients treated with thalidomide containing regimens[J]. ASH Annual Meeting Abstracts, 2007, 110(11): 310.
11. Richardson PG, Mitsiades C, Schlossman R, et al. Bortezomib in the front-line treatment of multiple myeloma[J]. Expert Rev Anticancer Ther, 2008, 8(7): 1054-1072.
12. Kristinsson SY. Thrombosis in multiple myeloma[J]. Hematology, 2010, 2010(1): 437-444.

West China Medical Journal

Thrombotic Complications in Multiple Myeloma: A Case Report and the Literature Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content